Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Sepsis Diagnostics Market Research Report Information By Technology (Molecular diagnostics, Biomarkers, Immunoassays), By Type (Kits, Instruments, And Blood culture media), By End User (Pathology laboratories, Specialty clinics, Hospitals, And Diagnostic centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030


ID: MRFR/MED/1574-HCR | 85 Pages | Author: Kinjoll Dey| May 2024

Global Sepsis Diagnostics Market Overview


Sepsis Diagnostics Market Size was valued at USD 1.1 billion in 2021. The Sepsis Diagnostics market industry is projected to grow from USD 1.20 Billion in 2022 to USD 2.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.80% during the forecast period (2024 - 2030). Factors including the high prevalence of sepsis, growing public awareness, and the development of cutting-edge diagnostic techniques are the key market drivers enhancing the market growth.


Sepsis Diagnostics Market Overview


 Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Oxford Nanopore and Day Zero Diagnostics (DZD) announced in 2023 that they would be working together to create a comprehensive diagnostic system for bloodstream infections, which are a major source of sepsis. The businesses will work together to integrate and improve a diagnostic technology that will enable same-day detection and genomic-based antibiotic susceptibility profile without blood culture in clinical environments like hospitals. In the future, the firms intend to pursue regulatory clearances, including those from the FDA.


Leading molecular diagnostics business Inflammatix, Inc. (2023) announced today that it has finished developing the TriVerityTM Acute Infection and Sepsis Test System (which comprises the MyrnaTM Instrument) and TriVerityTM Cartridge. TriVerity is designed to evaluate the possibility of a bacterial infection, a viral infection, and the risk of acute decompensation in patients with suspected acute infection and sepsis in emergency department settings.


The IntelliSep sepsis test was commercially released in the United States in 2023 by Cytovale, a medical diagnostic business. The test was started after receiving US Food and Drug Administration 510(k) clearance in December of last year. Adults with infection-related signs and symptoms can receive a prompt diagnosis of sepsis thanks to the test's ten-minute turnaround time.


The market expansion is being enhanced by many factors, like the rising prevalence of sepsis, increasing public awareness, and advancements in diagnostic procedures. The expansion of the sepsis diagnostics market is primarily driven by factors such as the incidence of sepsis, hospital-acquired infections, pneumonia cases, the increasing number of sepsis procedures, and augmented funding for sepsis-related research activities. One of the most prevalent outcomes experienced by persons receiving medical care in hospitals is the acquisition of nosocomial infections.


Therefore, the increasing incidence of sepsis and the growing allocation of funds towards research endeavors for sepsis diagnosis throughout the projected timeframe will contribute to the overall expansion of the sepsis diagnostic market. Hence, the prevalence of this medical condition has contributed to the worldwide compound annual growth rate (CAGR) of the Sepsis Diagnostics market in recent times.


June 2023, The ImmunoScore, developed by Prenosis Inc. in the United States, is a digital diagnostic tool that use Artificial Intelligence/Machine Learning (AI/ML) to predict sepsis. It is a host-based diagnosis that considers both clinical characteristics and protein biomarkers, making it independent of specific pathogens. Prenosis has established an extensive and rapidly expanding dataset and biobank comprising individuals who have been diagnosed with sepsis and several other infectious conditions. Prenosis has successfully built a substantial dataset and biobank for cases of acute care infections through collaboration with more than 10 institutions in the United States.


Sepsis Diagnostics Market Trends



  • Growing burden of sepsis to boost market growth


The prevalence of sepsis, the prevalence of hospital-acquired infections, the number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in financing for sepsis-related research activities are the main drivers of the growth of the sepsis diagnostics market. The most typical consequence for individuals being treated in hospitals is an infection picked up there. For instance, the Centers for Disease Control and Prevention (CDC) reported in 2021 that between 2019 and 2020 in the United States, there was an increase of about 24%, 35%, and 15% in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. The use of sepsis diagnostic devices will expand as bloodstream infections rise.


In Seattle, Washington, in April 2020, almost 75% of COVID-19 patients showed a suppressed immune response, and about 30% of patients had indications of liver impairment, according to the Sepsis Alliance. According to the Sepsis Alliance, COVID-19, influenza, pneumonia, meningitis, and other viruses are the main causes of sepsis. According to a retrospective study, COVID-19 patients who are hospitalized are more likely to get coinfections. According to the study, almost 50% of patients who did not survive had a secondary infection, almost 100% had sepsis, and about 70% had septic shock.


The use of sepsis diagnostic devices will expand as bloodstream infections rise. Additionally, in June 2021, funding of more than GBP 3 million was awarded to the University of Liverpool-led collaboration for a fresh initiative that will actively prevent, treat, and assess maternal sepsis. Thus, the rising prevalence of sepsis and the rising funding for research activities for sepsis diagnosis over the forecast period would drive the overall growth of the sepsis diagnosis market. Therefore, such medical condition has enhanced the Sepsis Diagnostics market CAGR globally in recent years.


However, the rising prevalence of sepsis is another factor driving the growth of the Sepsis Diagnostics market revenue.


Sepsis Diagnostics Market Segment Insights


Sepsis Diagnostics Type Insights


Based on Technology, the Sepsis Diagnostics market segmentation includes molecular diagnostics, biomarkers, and immunoassays. The molecular diagnostics segment held the majority share in 2021, contributing to around ~65-67% of the Sepsis Diagnostics market revenue. The segment is expected to be driven by the adoption of molecular diagnostic technology because of its many benefits, including high sensitivity, accuracy, and quick turnaround times compared to other technologies. This technique's drawback is that it cannot detect impossible organisms to cultivate. However, following blood culture, the molecular diagnostics technique is a standard method for identifying pathogens.


Sepsis Diagnostics Type Insights


Based on type, the Sepsis Diagnostics market segmentation includes kits, instruments, and blood culture media. The blood culture media segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is because clinicians view blood cultures as the most practical and economical testing method. The market has been divided into three product categories based on products: equipment, blood culture media, and test kits & reagents. A study on sepsis patients in Thailand found that the Septifast assay, a PCR-based technique, provided superior diagnostic performance than blood cultures. Hence, rising applications for Sepsis Diagnostics positively impact the market growth.


Sepsis Diagnostics End User Insights


Based on End User, the Sepsis Diagnostics industry has been segmented into pathology laboratories, Specialty clinics, hospitals, and diagnostic centers. Pathology laboratories held the largest segment share in 2021, mostly because lab testing is more accurate than POC testing for diagnosing sepsis. An extensive examination of the microorganism and its medication resistance profile is provided by clinical laboratory testing. Furthermore, routine assessment of lactate levels, a vague but helpful indication of sepsis, is successfully carried out in lab settings. The dependence of the general public and medical professionals on these labs has dramatically expanded with the introduction of technologically enhanced products. Due to the quick diagnosis and improved accuracy, the laboratory testing type sector is anticipated to increase at the quickest rate over the projection period. Additionally, it is anticipated that the rising number of diagnostic labs will help this segment grow throughout the projection period.


The fastest growing segment in the Sepsis Diagnostics industry is hospitals. The higher occurrence of hospital-transmitted infections and the rising number of surgical procedures conducted.


Figure 2: Sepsis Diagnostics Market, by End User, 2023 & 2030 (USD Billion)


Sepsis Diagnostics Market, by End User, 2023 & 2030


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


August 2023, FirstHealth of the Carolinas, a nonprofit health institution operating four hospitals in North Carolina, United States, will employ Immunexpress' SeptiCyte Rapid test to aid in distinguishing cases of sepsis-positive individuals from those exhibiting infection-negative systemic inflammation. According to Immunexpress, the cartridge-based test assesses the relative expression levels of genes associated with a patient's immunological response to infection. This test produces a score that reflects the probability of sepsis. The methodology employed involves the utilization of reverse transcription polymerase chain reaction (RT-PCR) technology for the purpose of quantifying the relative expression levels of host-response genes that have been extracted from whole blood.


August 2023, Cytovale, a medical diagnostic business, commenced the commercial launch of their latest diagnostic tool, known as the IntelliSep sepsis test, within the United States. The test was initiated subsequent to receiving 510(k) approval from the US Food and Drug Administration in December of the previous year. The test possesses the capacity to provide findings within a span of 10 minutes, hence facilitating prompt identification of sepsis in adult individuals exhibiting indications and symptoms of infection. The patients are categorized into three groups depending on their sepsis likelihood by utilizing a conventional blood sample. The findings have the potential to provide healthcare practitioners with a valuable instrument for improving clinical outcomes and optimizing resource use in hospitals, hence resulting in operational enhancements.


Sepsis Diagnostics Regional Insights


By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Sepsis Diagnostics market accounted for USD 0.457 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This development can be linked to the region's increased use of advanced diagnostic tools due to strong healthcare infrastructure. Additionally, this area's market growth is fueled by the substantial presence of important competitors and a favorable reimbursement system. Additionally, it is anticipated that the rising prevalence of infectious illnesses and sepsis will increase the need for cutting-edge diagnostic methods.


Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: Sepsis Diagnostics MARKET SHARE BY REGION 2023 (%) 


Sepsis Diagnostics MARKET SHARE BY REGION 2023


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe Sepsis Diagnostics market accounts for the second-largest market share. Rising research and development expenditures for sepsis diagnostics are anticipated to benefit the sector. Because of the area's advanced healthcare system, sepsis diagnostic tools are frequently used in diagnostic labs and centers. Further, the Germany Sepsis Diagnostics market held the largest market share, and the UK Sepsis Diagnostics market was the fastest growing market in the European region.


The Asia-Pacific Sepsis Diagnostics Market is expected to grow at the fastest CAGR from 2024 -2030. The a growing need for sepsis diagnostic tools in nations like Algeria and Morocco, where infectious illness frequency is significant. Moreover, the China Sepsis Diagnostics market held the largest market share, and the India Sepsis Diagnostics market was the fastest-growing market in the Asia-Pacific region.


Sepsis Diagnostics Key Market Players & Competitive Insights


Major market companies are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for sepsis diagnostics. With significant key developments like new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their presence. To grow and thrive in a market that is becoming more and more competitive and volatile, competitors in the Sepsis Diagnostics industry must provide affordable products.


Manufacturing locally to cut operational costs is one of the main business tactics used by manufacturers in the worldwide Sepsis Diagnostics industry to benefit customers and increase the market sector. In recent years, Sepsis Diagnostics industry has provided medicine with some of the most significant benefits. The Sepsis Diagnostics market major player such as Cytovale Inc, Immunexpress, and blood culture media are working to expand the market demand by investing in research and development activities.


They are a remarkable team of biologists, data scientists, engineers, previous healthcare professionals, investors, and caring individuals at Cytovale. They have a vision for bringing extremely complicated, life-threatening diseases into sharp and immediate focus. In April 2020, The Biomedical Advanced Research and Development Authority, or BARDA, and Cytovale Inc. have partnered to increase the use of Cytovale's Rapid Sepsis Diagnostic System for sepsis diagnosis in patients with probable respiratory infections, such as COVID-19.


Also, Immunexpress is creating technology to confirm or disprove sepsis in people with a history of infection. The overtreatment of sepsis caused by unreliable diagnoses places a heavy cost on healthcare systems, hospitals, doctors, nurses, payers, and antibiotic stewardship initiatives. In October 2020, On the Idylla platform from Biocartis, Immunexpress introduced the fast SeptiCyte, a one-hour molecular diagnostic test for sepsis. This one is one of the first quick, comprehensively integrated, and immune response-based diagnostics to help clinicians diagnose sepsis.


Key Companies in the Sepsis Diagnostics market includes



  • Sandstone Diagnostics Inc. (US)

  • T2 Biosystems

  • Immunexpress (US)

  • Axis-Shield Diagnostics Ltd. (Scotland)

  • Becton Dickinson and Company (US)

  • EKF Diagnostics (UK)

  • Cube Dx GmbH (Austria)

  • Wolters Kulwer N.V. (Netherlands)

  • Amara Health (US), among others


Sepsis Diagnostics Industry Developments


July 2023: Cytovale Inc. announced commercial launch of the Intellisep Test in United States. The diagnosis test is designed to be used in emergency departments to quickly diagnose sepsis patients presenting with signs of infection. 


January 2023: Cytovale Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance IntelliSep test. The test helps in the early detection of sepsis in adult patients with signs and symptoms of infection that visit emergency departments (ED).


Sepsis Diagnostics Market Segmentation


Sepsis Diagnostics Type Outlook



Sepsis Diagnostics Type Outlook



  • Kits

  • Instruments

  • Blood culture media


Sepsis Diagnostics End User Outlook



  • Pathology laboratories

  • Specialty clinics

  • Hospitals

  • Diagnostic centers


Sepsis Diagnostics Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Attribute/Metric Details
Market Size 2021 USD 1.1 billion
Market Size 2022 USD 1.20 billion
Market Size 2030 USD 2.32 billion
Compound Annual Growth Rate (CAGR) 9.80% (2024-2030)
Base Year 2023
Market Forecast Period 2024-2030
Historical Data 2018 & 2020
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Technology, Type, End User, and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled M Sandstone Diagnostics Inc. (US), T2 Biosystems, Immunexpress (US), Axis-Shield Diagnostics Ltd. (Scotland), Becton Dickinson and Company (US), EKF Diagnostics (UK), Cube Dx GmbH (Austria), Wolters Kulwer N.V. (Netherlands),Amara Health (US)
Key Market Opportunities Emergence of hospital-acquired infections
Key Market Dynamics Rising prevalence of sepsis has led to a growing need for its early diagnosis


Frequently Asked Questions (FAQ) :

The Sepsis Diagnostics market size was valued at USD 1.1 Billion in 2021.

The market is projected to grow at a CAGR of 9.80% during the forecast period, 2024-2030.

North America had the largest share in the market

The key players in the market are M Sandstone Diagnostics Inc. (US), T2 Biosystems, Immunexpress (US), Axis-Shield Diagnostics Ltd. (Scotland), Becton Dickinson and Company (US).

The molecular diagnostics category dominated the market in 2021.

The blood culture mediahad the largest share in the market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.